← Oncology Approval Tracker

FDA DECISION ·

Besremi

ropeginterferon alfa-2b-njft · PharmaEssentia

FDA approvalNew or expanded indicationEssential thrombocythemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with essential thrombocythemia.

LAMPGEN ANALYSIS

Why it matters

The indication extends a long-acting interferon to a second myeloproliferative neoplasm. The FDA-reviewed study compared it with anagrelide after resistance or intolerance to hydroxyurea.

What research teams should watch

Track prior cytoreductive therapy and longitudinal blood counts. Separate the approved indication from the prior-treatment population enrolled in SURPASS ET.

PRIMARY RECORDS

Sources